Cliff Asness's SUPN Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 98,257 shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $5.08 M, representing 0.00% of the portfolio. First purchased in 2014-Q2, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Cliff Asness has maintained a long-term strategic position in SUPN, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2014, adding 106,571 shares. Largest reduction occurred in Q4 2015, reducing 65,709 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Supernus Pharmaceuticals (SUPN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Supernus Pharmaceuticals (SUPN) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | -27,973 | Reduce 22.16% | 98,257 | $51.69 |
| Q4 2025 | -10,197 | Reduce 7.47% | 126,230 | $49.70 |
| Q3 2025 | -4,130 | Reduce 2.94% | 136,427 | $47.79 |
| Q2 2025 | +55,333 | Add 64.93% | 140,557 | $31.52 |
| Q1 2025 | +22,182 | Add 35.19% | 85,224 | $32.75 |
| Q4 2024 | +3,231 | Add 5.40% | 63,042 | $36.16 |
| Q3 2024 | +45,857 | Add 328.63% | 59,811 | $31.18 |
| Q2 2024 | +219 | Add 1.59% | 13,954 | $26.75 |
| Q1 2024 | -3,690 | Reduce 21.18% | 13,735 | $34.11 |
| Q4 2023 | +4,129 | Add 31.05% | 17,425 | $28.94 |
| Q3 2023 | +2,648 | Add 24.87% | 13,296 | $27.57 |
| Q2 2023 | +110 | Add 1.04% | 10,648 | $30.06 |
| Q1 2023 | -905 | Reduce 7.91% | 10,538 | $36.23 |
| Q4 2022 | +3,229 | Add 39.31% | 11,443 | $35.67 |
| Q3 2022 | +468 | Add 6.04% | 8,214 | $33.84 |
| Q2 2022 | +7,746 | New Buy | 7,746 | $28.92 |
| Q4 2021 | -8,887 | Sold Out | 0 | $0.00 |
| Q3 2021 | +8,887 | New Buy | 8,887 | $26.67 |
| Q2 2021 | -8,942 | Sold Out | 0 | $0.00 |
| Q1 2021 | -39,385 | Reduce 81.50% | 8,942 | $26.17 |
| Q4 2020 | -19,374 | Reduce 28.62% | 48,327 | $25.16 |
| Q3 2020 | -16,034 | Reduce 19.15% | 67,701 | $20.84 |
| Q2 2020 | +38,925 | Add 86.87% | 83,735 | $23.75 |
| Q1 2020 | +44,810 | New Buy | 44,810 | $17.99 |
| Q4 2019 | -14,950 | Sold Out | 0 | $0.00 |
| Q3 2019 | -5,300 | Reduce 26.17% | 14,950 | $27.49 |
| Q2 2019 | +5,026 | Add 33.01% | 20,250 | $33.09 |
| Q1 2019 | +175 | Add 1.16% | 15,224 | $35.01 |
| Q4 2018 | -17,617 | Reduce 53.93% | 15,049 | $33.22 |
| Q3 2018 | -51,650 | Reduce 61.26% | 32,666 | $50.36 |
| Q2 2018 | -49,072 | Reduce 36.79% | 84,316 | $59.85 |
| Q1 2018 | +49,097 | Add 58.25% | 133,388 | $45.80 |
| Q4 2017 | -3,338 | Reduce 3.81% | 84,291 | $39.85 |
| Q3 2017 | +1,265 | Add 1.46% | 87,629 | $40.00 |
| Q2 2017 | -3,802 | Reduce 4.22% | 86,364 | $43.10 |
| Q1 2017 | +8,672 | Add 10.64% | 90,166 | $31.30 |
| Q4 2016 | -23,912 | Reduce 22.69% | 81,494 | $25.25 |
| Q3 2016 | -43,750 | Reduce 29.33% | 105,406 | $24.73 |
| Q2 2016 | -21,914 | Reduce 12.81% | 149,156 | $20.37 |
| Q1 2016 | +24,740 | Add 16.91% | 171,070 | $15.25 |
| Q4 2015 | -65,709 | Reduce 30.99% | 146,330 | $13.44 |
| Q3 2015 | +55,093 | Add 35.10% | 212,039 | $14.03 |
| Q2 2015 | +23,475 | Add 17.59% | 156,946 | $16.98 |
| Q1 2015 | -49,700 | Reduce 27.13% | 133,471 | $12.09 |
| Q4 2014 | +106,571 | Add 139.13% | 183,171 | $8.30 |
| Q3 2014 | -14,600 | Reduce 16.01% | 76,600 | $8.69 |
| Q2 2014 | +91,200 | New Buy | 91,200 | $10.95 |
Cliff Asness's Supernus Pharmaceuticals Investment FAQs
Cliff Asness first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q2 2014, acquiring 91,200 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Supernus Pharmaceuticals, Inc. (SUPN) for 47 quarters since Q2 2014.
Cliff Asness's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q4 2014, adding 183,171 shares worth $1.52 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 98,257 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $5.08 M.
As of the Q1 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 212,039 shares, as reported at the end of Q3 2015.